HomeHealthUCC receives €5.6 million for new IBD research lab

UCC receives €5.6 million for new IBD research lab

World renowned researcher in IBD, Professor Subrata Ghosh, will establish a new laboratory focusing on IBD, Crohn’s Disease and Ulcerative Colitis at the APC Microbiome Ireland SFI Research Centre in UCC

€5.6 million in funding has been awarded to Prof Subrata Ghosh, a global leader in research into IBD, Crohn’s disease and ulcerative colitis, to establish a world-leading research lab at University College Cork (UCC), through a prestigious Science Foundation Ireland Research Professorship Programme award.

Prof Ghosh will lead the new AUGMENT project at UCC’s APC Microbiome Ireland SFI Research Centre to investigate precision medicine in relation to gut inflammation and the microbiome. This will contribute to furthering research in IBD, Crohn’s Disease and Ulcerative Colitis, which affect 40,000 people in Ireland and ten million people globally every year.

The grant will resource a science research lab and equipment, as well as 13 personnel. They will investigate the nascent area of the microbiome in relation to gut inflammation, and how it can be influenced by precision medicine to address critical health challenges.

Prof Ghosh is a Fellow of the Academy of Medical Sciences, UK, and a Fellow of the Canadian Academy of Health Sciences, the highest honours bestowed for leadership in life sciences and health research in those countries.

Prof Ghosh says that many of the important clues as to what causes Crohn’s Disease and Ulcerative Colitis, both of which are currently incurable, are emerging from research in UCC.

“Chronic inflammatory diseases and cancer are major causes of disability and death in Ireland and in the world. Current treatments are limited by their efficacy ceiling and adverse effects” he said.

“Increasing the efficacy of currently used targeted therapies and minimising adverse events through modulation of the gut microbiome may have a major impact on the life of the sufferers and address the economic burden of expensive therapies that prove to be ineffective.

“This SFI Research Professorship Award aims to work with those affected by chronic inflammatory diseases and cancer to find novel solutions that enhance the efficacy of current drugs, and minimises the harmful side-effects by understanding the role of the gut microbiome in mediating the action of drugs.”

Source link